Jim Hsiang, MD
Radiation Oncology · Corpus Christi, TXNPI 1164531273
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $186,501 of the $258,260 with a category attached, or 72.2%. 29 manufacturers reported payments, led by Dendreon Pharmaceuticals LLC at 44.5% of the total. Reporting peaked in 2023 at $75,608 and has fallen 59.8% since, to $30,387 in 2025. Among radiation oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 608 payments — averaging $424.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dendreon Pharmaceuticals LLC$115K
- Astellas Pharma US Inc$97K
- Amgen$23K
- Astellas Pharma Global Development$8K
- Johnson & Johnson$5K
- Pfizer$5K
- plus $6K from 23 others
What the payments were for
- Consulting fees$16,1356%
- Speaking & faculty fees$186,50172%
- Travel & lodging$44,17517%
- Food & beverage$10,7474%
- Education$7020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dendreon Pharmaceuticals LLC | 130 | $114,815 |
| Astellas Pharma US Inc | 134 | $96,605 |
| Amgen | 49 | $22,857 |
| Astellas Pharma Global Development | 6 | $7,810 |
| Johnson & Johnson(2 entities) | 118 | $5,028 |
| Pfizer | 50 | $4,957 |
| Bayer | 19 | $2,613 |
| Boston Scientific | 24 | $1,506 |
| AstraZeneca | 11 | $306 |
| Blue Earth Diagnostics | 13 | $257 |
| Myriad Genetic Laboratories, Inc. | 5 | $224 |
| Merck | 10 | $211 |
| Novartis | 7 | $168 |
| Myovant Sciences Inc. | 6 | $136 |
| Janssen Scientific Affairs, LLC | 1 | $124 |
| Siemens Medical Solutions USA, Inc. | 2 | $107 |
| Sumitomo Pharma America, Inc. | 3 | $79 |
| Seagen Inc. | 1 | $76 |
| Caris MPI, Inc. | 3 | $69 |
| Radius Health, Inc. | 3 | $56 |
| Foundation Medicine, Inc. | 3 | $43 |
| Progenics Pharmaceuticals, Inc. | 2 | $42 |
| Palette Life Sciences, Inc. | 1 | $37 |
| Clovis Oncology, Inc. | 2 | $32 |
| Teleflex LLC | 1 | $23 |
| Telix Pharmaceuticals | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
| Urovant Sciences Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$258,260 in reported general payments places this provider in the 95th percentile of 418 radiation oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 352 | $4,931,781 |
| ErleadaApalutamide | 90 | $1,286,666 |
| XgevaDenosumab | 28 | $94,708 |
| Abiraterone Acetate | 15 | $50,391 |
| ProliaDenosumab | 22 | $37,908 |
| Tamsulosin Hcl | 80 | $393 |
| Prednisone | 13 | $19 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $96,605 | $4,931,781352 claims |
| Johnson & JohnsonErleada | $5,028 | $1,286,66690 claims |
| AmgenXgeva, Prolia | $22,857 | $132,61650 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $124 | $50,39115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 418 radiation oncology providers in Texas.
Other radiation oncology in Corpus Christi
- James WelshHouston$421K
- Stephen ChunHouston$344K
- Chad TangHouston$183K
- Phuoc TranHouston$177K
- Hak ChoyDallas$119K
- Steven LinHouston$105K
- Benjamin SchrankHouston$100K
- Robert TimmermanDallas$77K
- Abhilasha PatelHouston$76K
- Puneeth IyengarDallas$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.